Background: Helicobacter pylori is a bacterium associated with gastroduodenal disease and gastric cancer. Empirical therapy in the treatment of H. pylori infection increases the risk of apparition of antimicrobial drug resistance. In a previous report, in H. pylori clinical isolates, resistance rates to commonly used antimicrobial drugs were as follows: metronidazole 82%, clarithromycin 3.8%, and amoxicillin 1.9%. The aim was to establish the variation of resistance rates and the detection of H. pylori genetic mutations isolated from dyspeptic patients. Methods: Antimicrobial susceptibility profiles were performed by the E-test method for metronidazole, clarithromycin, amoxicillin, and tetracycline in 61 clinical isolates. Sequencing was performed to detect mutations associated with resistance to clarithromycin. Results: According to our results, resistance rates found in the 61 isolates were 78.60% for metronidazole and 8.20% for clarithromycin. None of the studied isolates had resistance to tetracycline and amoxicillin. Secondary resistance rates displayed an increase when compared to primary rates for metronidazole (87.50 vs. 77.35%) and for clarithromycin (25.66 vs. 5.66%). Of 5 isolates resistant to clarithromycin, 3 had the A2143G mutation. By comparing the results in this work with previous reports, antimicrobial drug resistance rates did not show major modifications for metronidazole, amoxicillin, and tetracycline during the last 10 years. For clarithromycin, the resistance rate showed a moderate increase; nevertheless, it remains low (<15%) and this change was not statistically significant. Conclusion: Together, all findings in this work indicate that these antimicrobial drugs can still be used as first line of defense on infected patients living in this region of the country.

Keywords:
Helicobacter pylori, Antimicrobials, Resistance, Clarithromycin-resistance, Metronidazole-resistance, Colombia
1.
Fischbach W, Malfertheiner P. Helicobacter Pylori Infection. Dtsch Arztebl Int. 2018 Jun;115(25):429–36.
2.
Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol. 2014 Aug;20(29):9898–911.
3.
Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, et al.; European Helicobacter Study Group. Management of Helicobacter pylori infection–the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646–64.
4.
Olokoba AB, Obateru OA, Bojuwoye MO. Helicobacter pylori eradication therapy: A review of current trends. Niger Med J. 2013 Jan;54(1):1–4.
5.
Otero Regino W, Trespalacios AA, Otero E. Helicobacter pylori: Tratamiento actual. Un importante reto en gastroenterología. Rev Colomb Gastroenterol. 2009;24:273–86.
6.
Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol. 2017 Apr;23(16):2854–69.
7.
Otero RW, Gómez ZM, Otero PL, Trespalacios RA. [Helicobacter pylori: How do we treat it in 2018?]. Rev Gastroenterol Peru. 2018 Jan-Mar;38(1):54–63.
8.
Otero W, Trespalacios AA, Otero L, Vallejo MT, Amaya MT, Pardo R, et al. Guía de práctica clínica para el diagnóstico y tratamiento de la infección por Helicobacter pylori en adultos. Rev Colomb Gastroenterol. 2015;30:17–33.
9.
Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. World J Gastroenterol. 2014 Oct;20(40):14973–85.
10.
Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004 Sep;53(9):1374–84.
11.
Trespalacios AA, Otero Regino W, Mercado Reyes M. Helicobacter pylori resistance to metronidazole, clarithromycin and amoxicillin in Colombian patients. Rev Colomb Gastroenterol. 2010;25:31–8.
12.
Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther. 2004 Nov;20(10):1071–82.
13.
Xie Y, Zhu Z, Wang J, Zhang L, Zhang Z, Lu H, et al.; the Chinese Study Group on Helicobacter pylori, Chinese Society of Gastroenterology. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China. Antimicrob Agents Chemother. 2018 Aug;62(9):e00432–18.
14.
Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88(1):33–45.
15.
Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol. 2011 Sep;17(35):3971–5.
16.
Peretz A, Paritsky M, Dinisman-Zavulunov E, Pastukh N, Glyatman T, On A. Susceptibility of Helicobacter pylori to Levofloxacin and Rifampicin in Israel. Microb Drug Resist. 2015 Aug;21(4):448–51.
17.
Mendonça S, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter. 2000 Jun;5(2):79–83.
18.
Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clin Gastroenterol Hepatol. 2015 Sep;13(9):1616–24.
19.
Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Mellado P, Monteagudo I, Llorca J, et al. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother. 2012 Jan;67(1):170–3.
20.
Caliskan R, Tokman HB, Erzin Y, Saribas S, Yuksel P, Bolek BK, et al. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop. 2015 May-Jun;48(3):278–84.
21.
Boyanova L, Davidkov L, Gergova G, Kandilarov N, Evstatiev I, Panteleeva E, et al. Helicobacter pylori susceptibility to fosfomycin, rifampin, and 5 usual antibiotics for H. pylori eradication. Diagn Microbiol Infect Dis. 2014 Jul;79(3):358–61.
22.
Trespalacios AA, Rimbara E, Otero W, Reddy R, Graham DY. Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of Helicobacter pylori in gastric biopsies: identification of N87I mutation in GyrA. Diagn Microbiol Infect Dis. 2015 Apr;81(4):251–5.
23.
Gong Y, Yuan Y. Resistance mechanisms of Helicobacter pylori and its dual target precise therapy. Crit Rev Microbiol. 2018 May;44(3):371–92.
24.
López-Gasca M, Peña J, García-Amado MA, Michelangeli F, Contreras M. Point Mutations at gyrA and gyrB Genes of Levofloxacin-Resistant Helicobacter pylori Isolates in the Esophageal Mucosa from a Venezuelan Population. Am J Trop Med Hyg. 2018 Apr;98(4):1051–5.
25.
Dong F, Ji D, Huang R, Zhang F, Huang Y, Xiang P, et al. Multiple Genetic Analysis System-Based Antibiotic Susceptibility Testing in Helicobacter pylori and High Eradication Rate With Phenotypic Resistance-Guided Quadruple Therapy. Medicine (Baltimore). 2015 Nov;94(47):e2056.
26.
Ribeiro ML, Gerrits MM, Benvengo YH, Berning M, Godoy AP, Kuipers EJ, et al. Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP. FEMS Immunol Med Microbiol. 2004 Jan;40(1):57–61.
27.
Nishizawa T, Suzuki H. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci. 2014 Oct;1:19.
28.
Cambau E, Allerheiligen V, Coulon C, Corbel C, Lascols C, Deforges L, et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol. 2009 Nov;47(11):3600–7.
29.
Zhao LJ, Huang YQ, Chen BP, Mo XQ, Huang ZS, Huang XF, et al. Helicobacter pylori isolates from ethnic minority patients in Guangxi: resistance rates, mechanisms, and genotype. World J Gastroenterol. 2014 Apr;20(16):4761–70.
30.
Chen J, Ye L, Jin L, Xu X, Xu P, Wang X, et al. Application of next-generation sequencing to characterize novel mutations in clarithromycin-susceptible Helicobacter pylori strains with A2143G of 23S rRNA gene. Ann Clin Microbiol Antimicrob. 2018 Mar;17(1):10.
31.
Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, et al. Noninvasive molecular analysis of Helicobacter pylori: is it time for tailored first-line therapy? World J Gastroenterol. 2017 Apr;23(14):2453–8.
32.
Alvarez A, Moncayo JI, Santacruz JJ, Santacoloma M, Corredor LF, Reinosa E. Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. Antimicrob Agents Chemother. 2009 Sep;53(9):4022–4.
33.
CLSI. M45 Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria. 3rd editio Wayne. PA: Clinical and Laboratory Standards Institute; 2016.
34.
The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0. 2019. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf.
35.
Ménard A, Santos A, Mégraud F, Oleastro M. PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. Antimicrob Agents Chemother. 2002 Apr;46(4):1156–7.
36.
Talebi Bezmin Abadi A. Diagnosis of Helicobacter pylori Using Invasive and Noninvasive Approaches. J Pathogens. 2018 May;2018:9064952.
37.
Selgrad M, Meissle J, Bornschein J, Kandulski A, Langner C, Varbanova M, et al. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1257–60.
38.
Siavoshi F, Saniee P, Khalili-Samani S, Hosseini F, Malakutikhah F, Mamivand M, et al. Evaluation of methods for H. pylori detection in PPI consumption using culture, rapid urease test and smear examination. Ann Transl Med. 2015 Jan;3(1):11.
39.
Malfertheiner P. Diagnostic methods for H. pylori infection: Choices, opportunities and pitfalls. United European Gastroenterol J. 2015 Oct;3(5):429–31.
40.
Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al.; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6–30.
41.
Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016 Feb;43(4):514–33.
42.
Acosta CP, Hurtado FA, Trespalacios AA. [Determination of single nucleotide mutations in the 23S rRNA gene of Helicobacter pylori related to clarithromycin resistance in a population from Cauca, Colombia]. Biomedica. 2014 Apr;34(suppl 1):156–62.
43.
Figueroa M, Cortés A, Pazos Á, Bravo LE. [Antimicrobial susceptibility of Helicobacter pylori with chronic gastritis]. Biomedica. 2012 Jan-Mar;32(1):32–42.
44.
Lee MG, Arthurs M, Smikle MF, Dowe G, Levy V, Barton EN. Antibiotic sensitivity of Helicobacter pylori in Jamaica. West Indian Med J. 2004 Dec;53(6):374–7.
45.
Henao Riveros SC, Quiroga A, Martínez Marín JD, Otero Regino W. Resistencia primaria a la claritromicina en aislamientos de Helicobacter pylori. Rev Colomb Gastroenterol. 2009;24(2):110–14.
46.
Otth L, Wilson M, Fernández H, Otth C, Toledo C, Cárcamo V, et al. Isolation of Helicobacter pylori in gastric mucosa and susceptibility to five antimicrobial drugs in Southern chile. Braz J Microbiol. 2011 Apr;42(2):442–7.
47.
Vega AE, Cortiñas TI, Puig ON, Silva HJ. Molecular characterization and susceptibility testing of Helicobacter pylori strains isolated in western Argentina. Int J Infect Dis. 2010 Sep;14(Suppl 3):e85–92.
48.
Torres-Debat ME, Pérez-Pérez G, Olivares A, Fernández L, Raisler K, González N, et al. Antimicrobial susceptibility of Helicobacter pylori and mechanisms of clarithromycin resistance in strains isolated from patients in Uruguay. Rev Esp Enferm Dig. 2009 Nov;101(11):757–62.
49.
Boyanova L, Gergova G, Evstatiev I, Spassova Z, Kandilarov N, Yaneva P, et al. Helicobacter pylori resistance to six antibiotics by two breakpoint systems and resistance evolution in Bulgaria. Infect Dis (Lond). 2016;48(1):56–62.
50.
Di Giulio M, Di Campli E, Di Bartolomeo S, Cataldi V, Marzio L, Grossi L, et al. In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy. Scand J Gastroenterol. 2016 Mar;51(3):263–9.
51.
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018 Nov;155(5):1372–1382.e17.
52.
Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al.; Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013 Jan;62(1):34–42.
53.
Vilaichone RK, Ratanachu-Ek T, Gamnarai P, Chaithongrat S, Uchida T, Yamaoka Y, et al. Extremely High Prevalence of Metronidazole-Resistant Helicobacter pylori Strains in Mountain People (Karen and Hmong) in Thailand. Am J Trop Med Hyg. 2016 Apr;94(4):717–20.
54.
Torres J, Camorlinga-Ponce M, Pérez-Pérez G, Madrazo-De la Garza A, Dehesa M, González-Valencia G, et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol. 2001 Jul;39(7):2677–80.
55.
Urrestarazu MI, Serrano N, Piñero R, Cavazza ME. Susceptibilidad de helicobacter pylori a los antimicrobianos. Rev Soc Venez Microbiol. 2003;23:14–5.
56.
Datta S, Chattopadhyay S, Patra R, De R, Ramamurthy T, Hembram J, et al. Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. Aliment Pharmacol Ther. 2005 Jul;22(1):51–7.
57.
Liou JM, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, et al.; Taiwan Gastrointestinal Disease and Helicobacter Consortium. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study. PLoS One. 2015 May;10(5):e0124199.
58.
Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol. 2009 Jul;58(Pt 7):930–5.
59.
Zhang YX, Zhou LY, Song ZQ, Zhang JZ, He LH, Ding Y. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. World J Gastroenterol. 2015 Mar;21(9):2786–92.
60.
Boyanova L, Hadzhiyski P, Kandilarov N, Markovska R, Mitov I. Multidrug resistance in Helicobacter pylori: current state and future directions. Expert Rev Clin Pharmacol. 2019 Sep;12(9):909–15.
61.
Francesco VD, Zullo A, Hassan C, Giorgio F, Rosania R, Ierardi E. Mechanisms of Helicobacter pylori antibiotic resistance: an updated appraisal. World J Gastrointest Pathophysiol. 2011 Jun;2(3):35–41.
62.
Quek C, Pham ST, Tran KT, Pham BT, Huynh LV, Luu NB, et al. Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam. F1000 Res. 2016 Apr;5:671.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.